Gastrointestinal Remedies - US - September 2006

TABLE OF CONTENTS

• Introduction and Abbreviations
• Introduction
• Definition
• Abbreviations and terms
• Abbreviations
• Terms
• Executive Summary
• Age, ethnicity, and lifestyle combine with self-care and switches
• Chewable tablets, flavoring, and combo products help grow market
• Antacids dominate segments
• Six manufacturers dominate
• TV, print begin to share with Web advertising
• The consumer
• Aging and ethnic populations, switches, retail environment impact the future
• Market forecast
• Market Drivers
• pIncidence of gastrointestinal ailments increases
  • Figure 1: U.S. population projections and number of GI ailment sufferers, by age, 2001-11
• Aging population equals windfall of GI industry
  • Figure 2: Incidence of gastrointestinal ailments, by type of ailment, by age, 2005
• Diet and stress contribute to incidence
  • Figure 3: Attitudes towards diet, September 2003-05
• Prescription switches to OTC
• Direct-to-consumer advertising boosts awareness
• Self-diagnosis and self-care continue momentum
• Insurance co-pay hikes
• Hispanic: A new generation of GI sufferers
  • Figure 4: U.S. Hispanic population projections and number of GI ailment sufferers, by age, 2001-11
• Market Size and Trends
• Market size
  • Figure 5: Total U.S. FDM retail sales of gastrointestinal remedies, at current and constant prices, 2001-06
  • Figure 6: Graph: Total U.S. FDM retail sales of gastrointestinal remedies, at current and constant prices,
• Market trends
  • Figure 7: New gastrointestinal remedy product launches by product type, 2001-06
  • Figure 8: Number of new gastrointestinal remedy products by price, 2001-06
• Market Segmentation
• Overview
  • Figure 9: FDM sales of gastrointestinal remedies, segmented by type, 2004 and 2006
  • Figure 10: Graph: FDM sales of gastrointestinal remedies, segmented by type, 2004 and 2006
• Antacids
  • Figure 11: FDM sales of antacids, at current and constant prices, 2001-06
• Laxatives
  • Figure 12: FDM sales of laxatives, at current and constant prices, 2001-06
• Stomach remedies
  • Figure 13: FDM sales of stomach remedies, at current and constant prices, 2001-06
• Anti-diarrheals
  • Figure 14: FDM sales of anti-diarrheals, at current and constant prices, 2001-06
• Supply Structure
• Companies and brands
  • Figure 15: Manufacturer FDM sales of gastrointestinal remedies in the U.S., 2004 and 2006
• Antacids
  • Figure 16: Manufacturer brand FDM sales of antacids in the U.S., 2004 and 2006
• Laxatives
  • Figure 17: Manufacturer brand FDM sales of laxatives in the U.S., 2004 and 2006
• Stomach remedies
  • Figure 18: Manufacturer brand FDM sales of stomach remedies in the U.S., 2004 and 2006
• Anti-diarrheals
  • Figure 19: Manufacturer brand FDM sales of anti-diarrheals in the U.S., 2004 and 2006
• Company profiles
• Procter & Gamble
• Johnson & Johnson
• GlaxoSmithKline
• Novartis Consumer Health
• Pfizer, Inc.
• Other companies
• Advertising and Promotion
• Introduction
  • Figure 20: Estimated online streaming media expenditures, 2004-10
• Procter & Gamble
  • Figure 21: Pepto Bismol ad featuring young basketball players, 2006
• GlaxoSmithKline
  • Figure 22: Tums ad featuring roadside diners, 2006
• Johnson & Johnson-Merck
  • Figure 23: Pepcid AC ad featuring "Jim" the adventurous eater, 2006
• Novartis
  • Figure 24: Maalox ad feauturing, 2006
• Pfizer
  • Figure 25: Rolaids ad featuring deflating tires, balloons, 2006
• McNeil
• Retail Distribution
• Introduction
  • Figure 26: U.S. retail FDM sales of gastrointestinal remedies, by channel, 2004 and 2006
• Drug stores
  • Figure 27: U.S. mass merchandiser and club store sales of GI remedies, at current and constant prices,
• Mass merchandisers and clubs
  • Figure 28: U.S. mass merchandiser sales of gastrointestinal remedies, at current and constant prices,
• Supermarkets
  • Figure 29: U.S. supermarket sales of gastrointestinal remedies, at current and constant prices,
• The Consumer
• Introduction
• Summary
• Incidence and severity of gastrointestinal ailments
  • Figure 30: Incidence of GI ailments, by age, January-September 2005
  • Figure 31: Severity of GI ailments, by age, January-September 2005
• Prescription vs. OTC
  • Figure 32: Use of prescription vs. OTC product to treat GI ailment, by age, January-September 2005
• Types/kinds of OTC remedies preferred
  • Figure 33: Types/kinds of OTC GI remedies preferred, January-September 2005
• Brands preferred
  • Figure 34: Heartburn/indigestion aid brands preferred, January-September 2005
• Frequency of use of heartburn/indigestion aids
  • Figure 35: Frequency of use of heartburn/indigestion aids, by age, January-September 2005
• Use of laxatives and types preferred
  • Figure 36: Use of laxatives and types preferred, by age, January-September 2005
• Laxative brands preferred
  • Figure 37: Laxative brands preferred, January-September 2005
• Frequency of laxative use
  • Figure 38: Frequency of use of laxatives, by age, January-September 2005
• Attitudes towards GI ailments and remedies
  • Figure 39: Attitudes towards GI ailments, by age, August 2006
  • Figure 40: Alka-Seltzer ad featuring elderly consumers, 2006
  • Figure 41: Attitudes towards GI remedies, by age, August 2006
  • Figure 42: Self or doctor diagnosis of GI ailments, by problem, by age, August 2006
  • Figure 43: Effectiveness of OTC GI Remedies, by problem, by age, August 2006
• Cohort analysis
• Incidence of GI ailments among cohorts
  • Figure 44: Incidence of GI ailments, by cohort, January-September 2005
• Use of heartburn/indigestion aids and laxatives among cohorts
  • Figure 45: Use of heartburn/indigestion aids and laxatives, by cohort, January-September 2005
• Race/ethnicity analysis
• Incidence of GI ailments among ethnicities
  • Figure 46: Incidence of GI ailments, by race/ethnicity, January-September 2005
• Use of heartburn/indigestion aids and laxatives among ethnicities
  • Figure 47: Use of heartburn/indigestion aids and laxatives, by race/ethnicity, January-September 2005
• Attitudes towards GI ailments and remedies among ethnicities
  • Figure 48: Attitudes towards GI ailments, by race/ethnicity, August 2006
  • Figure 49: Attitudes towards GI remedies, by race/ethnicity, August 2006
• Future and Forecast
• Future trends
• Aging population continues to grow
  • Figure 50: Total U.S. population, by age, 2001-11
• Prescription switches forecast to increase
• Hispanics represent growing opportunity
  • Figure 51: U.S. Hispanic population, 2001, 2006, & 2011
• Prilosec protects its role in the market
• Retail pharmacy expands its healthcare role
• Market forecast
• Gastrointestinal remedies
  • Figure 52: Forecast of total U.S. FDM sales of gastrointestinal remedies, at current and constant
  • Figure 53: Graph: Forecast of total U.S. FDM sales of gastrointestinal remedies, at current and constant prices, 2006-11
• Antacids
  • Figure 54: Forecast of U.S. FDM sales of antacids, at current and constant prices, 2006-11
• Laxatives
  • Figure 55: Forecast of U.S. FDM sales of laxatives, at current and constant prices, 2006-11
• Stomach remedies
  • Figure 56: Forecast of U.S. FDM sales of stomach remedies, at current and constant prices, 2006-11
• Anti-diarrheals
  • Figure 57: Forecast of U.S. FDM sales of anti-diarrheals, at current and constant prices, 2006-11
• Forecast factors
• Appendix: Trade Associations
• Appendix: New Product Developments
• New product briefs
• McKesson: Sunmark Woman's Laxative Tablets
• Procter & Gamble: Cinnamon Fiber Wafers
• Johnson & Johnson: Mylanta Ultimate Strength Antacid
• Pfizer: Rolaids Plus Antacid & Antigas Gas Relief
• GlaxoSmithKline: Gaviscon Extra Strength Antacid Extension
• Albertson's: Equaline Milk of Magnesia